- Home
- ALRN
as 12-17-2024 4:00pm EST
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 76.9M | IPO Year: | 2017 |
| Target Price: | $19.00 | AVG Volume (30 days): | 92.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.61 - $7.42 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Aileron Therapeutics Inc. (ALRN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| WINDSOR JAMES BRIAN | ALRN | President and CEO | Dec 5 '24 | Buy | $2.25 | 400 | $897.61 | 239 |
Latest Aileron Therapeutics Inc. News
ALRN Breaking Stock News: Dive into ALRN Ticker-Specific Updates for Smart Investing
PR Newswire
a month ago
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Benzinga
a month ago
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis
PR Newswire
a month ago
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
PR Newswire
2 months ago
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
PR Newswire
2 months ago
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
PR Newswire
3 months ago
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
PR Newswire
4 months ago
Aileron Therapeutics to Present at the 8th Annual IPF Summit
PR Newswire
4 months ago
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
Compare ALRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALRN Aileron Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.